¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

²Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

³Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.

⁴Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.

⁵Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon, Korea.

⁶Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.

⁷Division of Endocrinology, Department of Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea.

Corresponding author: Won Bae Kim. Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea. Tel: +82-2-3010-3913, Fax: +82-2-3010-6962, kimwb@amc.seoul.kr

Korean Thyroid Cancer Study Group (KTCSG): Min Ji Jeon, Won Gu Kim, Tae Yong Kim, Young Kee Shong, and Won Bae Kim (Division of Endocrinology and Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul); Hosu Kim, Young Nam Kim, Tae Hyuk Kim, Sun Wook Kim, and Jae Hoon Chung (Division of Endocrinology and Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul); Hee Kyung Kim and Ho-Cheol Kang (Department of Internal Medicine, Chonnam National University Medical School, Gwangju); Eun Heui Kim, Bo Hyun Kim, and In Joo Kim (Division of Endocrinology and Metabolism, Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan); Hyun-Seung Yi, Kun Soon Kim, and Minho Shong (Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University School of Medicine, Daejeon); Eun Sook Kim (Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan); and Eun Kyung Jang and Eui Young Kim (Department of Endocrinology, Dongnam Institute of Radiological & Medical Sciences Cancer Center, Busan, Korea).

Received 2017 May 24; Revised 2017 August 19; Accepted 2017 September 15.

Abstract

Background

Little is known regarding disease-specific mortality of differentiated thyroid cancer (DTC) patients and its risk factors in Korea.

Methods

We retrospectively reviewed a large multi-center cohort of thyroid cancer from six Korean hospitals and included 8,058 DTC patients who underwent initial surgery between 1996 and 2005.

Results

Mean age of patients at diagnosis was 46.2±12.3 years; 87% were females. Most patients had papillary thyroid cancer (PTC; 97%) and underwent total thyroidectomy (85%). Mean size of the primary tumor was 1.6±1.0 cm. Approximately 40% of patients had cervical lymph node (LN) metastases and 1.3% had synchronous distant metastases. During 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred; the 10-year disease-specific survival (DSS) rate was 98%. According to the year of diagnosis, the number of disease-specific mortality was not different. However, the rate of disease-specific mortality decreased during the study period (from 7.7% to 0.7%). Older age (≥45 years) at diagnosis, male, follicular thyroid cancer (FTC) versus PTC, larger tumor size (>2 cm), presence of extrathyroidal extension (ETE), lateral cervical LN metastasis, distant metastasis and tumor node metastasis (TNM) stage were independent risk factors of disease-specific mortality of DTC patients.

Conclusion

The rate of disease-specific mortality of Korean DTC patients was 1.9%; the 10-year DSS rate was 98% during 1996 to 2005. Older age at diagnosis, male, FTC, larger tumor size, presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stages were significant risk factors of disease-specific mortality of Korean DTC patients.

Keywords: Mortality; Risk factors; Thyroid neoplasms

INTRODUCTION

The incidence of thyroid cancer has increased worldwide and it is currently the most common cancer among Korean women [1]. Differentiated thyroid cancer (DTC), particularly papillary thyroid cancer (PTC) is the prominent pathologic subtype of thyroid cancer and accounts for the increasing incidence of thyroid cancer. Despite the increase in incidence, disease-specific mortality of thyroid cancer patients is low [2]; a recent study reported that the age-standardized mortality rate of thyroid cancer in Korea ranged from 0.19 to 0.67 per 100,000 individuals between 1985 and 2010 [3].

Although DTC is an indolent cancer with excellent prognosis, identifying the risk factors that predict DTC-related mortality is important. According to previous studies, older age, male sex, and tumor node metastasis (TNM) staging system by the American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) were prognostic determinants of DTC-specific mortality [4 5 6 7]. Furthermore, the presence of lymphovascular invasion or extranodal extension of the tumor was associated with mortality of PTC patients [8 9]. Molecular-based approaches demonstrated that the presence of the coexistence of telomerase reverse transcriptase (TERT) promoter and BRAF mutation is associated with mortality of PTC patients [10 11 12 13]. However, no multicenter study has evaluated the risk factors of disease-specific mortality of DTC patients in Korea.

This study aimed to evaluate the trends of disease-specific mortality of DTC patients in Korea using a large multicenter thyroid cancer cohort. We also analyzed the risk factors of disease-specific mortality of DTC patients in Korea.

METHODS

Study population

In this multi-center, retrospective cohort study, we reviewed the medical records of DTC patients who underwent their initial thyroid surgery between 1996 and 2005 at the following six hospitals in Korea: Asan Medical Center, Samsung Medical Center, Chonnam National University Hwasun Hospital, Pusan National University Hospital, Ulsan University Hospital, and Chungnam National University Hospital. We initially screened 8,360 DTC patients including those with PTC and follicular thyroid cancer (FTC). However, we excluded patients with <1-year follow-up or those with inadequate pathologic reports. Finally, 8,058 patients were eligible for the study.

We analyzed the incidence of disease-specific mortality of the patients and evaluated the patient age at diagnosis of DTC (≥45 years), sex, size of primary tumor (>2 cm), presence of extrathyroidal extension (ETE) of primary tumor, cervical lymph node (LN) metastasis, distant metastasis, and TNM stage on the basis of the 7th edition of the AJCC/UICC TNM staging system [14] as potential risk factors of disease-specific mortality. Our study protocol was approved by the Institutional Review Board of each institution (Asan Medical Center, 2016-1301; Samsung Medical Center, 2016-05-053; Chonnam National University Hwasun Hospital, CNUHH-2017-053; Pusan National University Hospital, 1701-014-051; Ulsan University Hospital, 2016-12-031; and Chungnam National University Hospital, CNUH 2017-01-018). Informed consent was waived due to retrospective design.

Statistics

R studio (version 3.4.0) and the R libraries survival, car, and gdata were used to analyze the data in this study (R Foundation for Statistical Computing, http://www.R-project.org/). Continuous variables are presented as mean±standard deviation, and categorical variables are presented as number (percentage). The chi-square test was used to compare variables according to the year of initial diagnosis. A Cox proportional hazard model was used to evaluate the risk factors of disease-specific mortality. Hazard ratios with 95% confidence intervals were also estimated. Disease-specific survival (DSS) curves was constructed using the Kaplan-Meier method with GraphPad Prism version 5.01 (GraphPad Software Inc., San Diego, CA, USA) and the log rank test was used to evaluate the differences in DSS on the basis of TNM stages. DSS was defined as the time interval between initial surgery and the last censoring or DTC-related death. All P values were two-sided, and P values of <0.05 were considered to be statistically significant.

RESULTS

Baseline characteristics

Table 1 shows the baseline characteristics of 8,058 DTC patients. The mean age of the patients at initial DTC diagnosis was 46.2±12.3 years, and 87% of patients were females. Approximately 85% of patients (n=6,831) underwent total thyroidectomy as the initial surgery and 5,837 patients (72%) underwent radioactive iodine ablation therapy. Most patients had PTC (7,780 patients, 97%) including its variants. The mean size of the primary tumor was 1.6±1.0 cm and 3,960 patients (49%) had ETE of the tumor. Cervical LN metastases were found in 3,218 patients (40%) including 865 patients (11%) with lateral cervical LN metastasis (N1b according to the 7th TNM staging system). At initial diagnosis, 108 patients (1.3%) had synchronous distant metastases. Based on the TNM staging system, 4,992 (72%), 196 (2%), 2,288 (28%), and 575 (7%) patients were classified into stage I, II, III, and IV, respectively.

Table 1

Baseline Characteristics of Differentiated Thyroid Cancer Patients

When we evaluated the baseline characteristics according to the year of initial diagnosis, DTCs diagnosed after 2000 was more likely to be PTCs and were smaller with less LN metastasis compared to DTCs diagnosed before 2000 (Table 2).

Table 2

Pathological Characteristics of Differentiated Thyroid Cancer Patients According to the Year of Initial Diagnosis

Time trends of disease-specific mortality of DTC patients

During 11.3 years of follow-up (interquartile range, 9.1 to 13.0), there were 309 mortality cases (3.8%) including 150 cases (1.9%) of disease-specific mortality. These 150 cases composed of 114 PTCs (76%) and 36 FTCs (24%) (Fig. 1A). Disease-specific mortality occurred at a median of 5.5 years after the initial surgery, and 29 patients (19%) were dead 10 years after the initial surgery. There were no significant differences in the characteristics according to the duration from the initial surgery to mortality event (Supplemental Table S1). The 5-, 10-, and 20-year DSS rates were 99%, 98%, and 94%, respectively (Fig. 2A). Fig. 1 shows the time trends of disease-specific mortality of DTC patients. On the basis of the year of initial DTC diagnosis, the number of disease-specific mortality cases was steady from 1996 to 2005, ranging from 10 to 21 cases each year (Fig. 1B). The incidence of disease-specific mortality decreased from 7.7% in 1997 to 0.7% in 2005 (Fig. 1C).

Fig. 1

Time trends of disease-specific mortality of differentiated thyroid cancer patients in Korea based upon the year of initial diagnosis. During a median of 11.3 years of follow-up, 150 disease-specific mortalities (1.9%) occurred. (A) Among 150 cases, 114 cases (76%) were papillary thyroid cancers (PTCs) and 36 cases (24%) were follicular thyroid cancers (FTCs). (B) The number of disease-specific mortality was steady and ranged from 10 to 21 cases. (C) The rate of disease-specific mortality decreased during the study period. The blank bar indicates small primary tumors (≤2 cm) and the black bar indicates large primary tumors (>2 cm).

Fig. 2

Disease-specific survival (DSS) curves of Korean differentiated thyroid cancer patients. (A) The 5-, 10-, and 20-year DSS rates were 99%, 98%, and 94%, respectively. (B) DSS was significantly different according to the 7th edition of the tumor node metastasis (TNM) staging system (P<0.001).

Risk factors of disease-specific mortality of DTC patients

To evaluate the risk factors for disease-specific mortality of DTC patients, we used a Cox-proportional hazard model. In univariate analysis, older age (≥45 years) at diagnosis, male, FTC, larger tumor size (>2 cm), presence of ETE, lateral cervical LN metastasis (N1b disease), distant metastasis, and TNM stage were significantly associated with disease-specific mortality of DTC patients. In multivariate analysis, all these factors were independent risk factors of disease-specific mortality of DTC patients. TNM staging was an independent risk factor of disease-specific mortality of DTC. No significant differences were found in the risk of disease-specific mortality between stage I and III (Table 3). Fig. 2B shows DSS curves based on the 7th edition of the TNM staging system and DSS was significantly different (P<0.001).

Table 3

Risk Factors of Disease-Specific Mortality of Differentiated Thyroid Cancer Patients

DISCUSSION

This is the first large multicenter cohort study to evaluate disease-specific mortality of 8,058 DTC patients in Korea. During the median of 11.3 years of follow-up, 150 patients (1.9%) died because of DTC, and the 10-year DSS rate was 98%. There were no significant changes in the number of disease-specific mortality with regard to the year of DTC diagnosis. Disease-specific mortality rates of DTC patients decreased during the study period. This trend and characteristics of disease-specific mortality of thyroid cancer patients was similar to that reported in the USA, which analyzed the data from the National Cancer Institute's Surveillance, Epidemiology, and End Results [6] and suggested a recent increase in the incidence of small, low-risk DTCs.

TNM staging according to the 7th edition of the TNM staging system was significantly associated with disease-specific mortality of DTC patients in our subjects [5 15]. Similar to previous studies [4 7 16], older age at diagnosis (≥45 years) was identified as an independent risk factor for disease-specific mortality of DTC patients in this study. Many studies suggested patient age to be a prognostic factor of disease-specific mortality of DTC patients. However, the age cutoff point is controversial. A recent study suggested that patient age was significantly and linearly associated with disease-specific mortality of PTC patients [4], and several studies suggested that a patient age of 55 years is more appropriate than 45 years for the cutoff point [17 18]. On the basis of these studies, the revised 8th edition of the AJCC/UICC TNM staging system changed the cutoff point of patient age from 45 years to 55 years [19]. In our subjects, patient age cutoff point of 55 also significantly differentiates the risk of disease-specific mortality of DTC patients. The diseasespecific mortality rate was 0.56% in younger patients (<55 years) and 5.89% in older patients (≥55 years).

Even though the 7th TNM staging system was associated with disease-specific mortality of DTC patients in this study, there were no significant differences in the risk of mortality of DTC patients between stage I and III. It is because the presence of minimal ETE up-staged small DTCs from T1 to T3 and classified them to stage III according to the 7th TNM staging system [14 20]. Recent studies presented the similar clinical outcomes of DTC patients with or without minimal ETE [21 22] and the revised 8th edition of the TNM staging system also changed the definition of T3 [19]. This new TNM staging system will be used from January 2018. Further studies are required to analyze the impact of altered cutoff point of patient age or the definition of T3 on disease-specific mortality of DTC patients in Korea.

In this study, male, larger tumor (>2 cm), presence of ETE, lateral cervical LN metastases, and distant metastases were significantly associated with disease-specific mortality of DTC patients, and these results are consistent with those previously reported [6 16]. In this study, FTC was also associated with a high risk of disease-specific mortality after adjusting for other risk factors compared with PTC. A previous study reported that FTC had similar mortality rates with PTC after excluding patients with distant metastases at diagnosis [7]. Our findings regarding FTC could be biased owing to relatively higher PTC incidence in Korea. More studies are required to evaluate the long-term outcomes of FTC compared with those of PTC.

Our study has some limitations. In this study, we could not evaluate the impact of lymphovascular invasion or extranodal extension on DTC-related mortality because of the lack of pathology data. We also could not evaluate the mutational profile of DTC on disease-specific mortality. Disease-specific mortality could be underestimated, owing to relatively short follow-up durations in this study. The median follow-up duration of our study subjects was 11.3 years. Disease-specific mortality occurred in a median of 5.5 years after the initial surgery, and 20% occurred 10 years after the initial surgery. Our study took advantage of a large, multicenter cohort of DTC in Korea to minimize selection bias.

In conclusion, the rate of disease-specific mortality of Korean DTC patients who were diagnosed DTC between 1996 and 2005 was 1.9%; the 10-year DSS rate was 98%. Older patient age (≥45 years) at diagnosis, male, FTC, larger tumor size (>2 cm), presence of ETE, lateral cervical LN metastasis, distant metastasis, and TNM stage were significant risk factors of disease-specific mortality Korean DTC patients.

ACKNOWLEDGMENTS

This study was supported by the Korean Endocrine Society of EnM Research Award 2016.

Notes

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

References

1. Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat 2016;48:436–450. 26987395.

2. Holmes D. Thyroid cancer: mortality unaffected by rise in use of imaging tests. Nat Rev Endocrinol 2016;12:560.

3. Choi YM, Kim TY, Jang EK, Kwon H, Jeon MJ, Kim WG, et al. Standardized thyroid cancer mortality in Korea between 1985 and 2010. Endocrinol Metab (Seoul) 2014;29:530–535. 25559576.

4. Adam MA, Thomas S, Hyslop T, Scheri RP, Roman SA, Sosa JA. Exploring the relationship between patient age and cancer-specific survival in papillary thyroid cancer: rethinking current staging systems. J Clin Oncol 2016;34:4415–4420. 27998233.

5. Pathak KA, Lambert P, Nason RW, Klonisch T. Comparing a thyroid prognostic nomogram to the existing staging systems for prediction risk of death from thyroid cancers. Eur J Surg Oncol 2016;42:1491–1496. 27265038.

6. Nilubol N, Kebebew E. Should small papillary thyroid cancer be observed? A population-based study. Cancer 2015;121:1017–1024. 25425528.

7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418–428. 7977430.

8. Pontius LN, Youngwirth LM, Thomas SM, Scheri RP, Roman SA, Sosa JA. Lymphovascular invasion is associated with survival for papillary thyroid cancer. Endocr Relat Cancer 2016;23:555–562. 27317633.

9. Suh S, Pak K, Seok JW, Kim IJ. Prognostic value of extranodal extension in thyroid cancer: a meta-analysis. Yonsei Med J 2016;57:1324–1328. 27593858.

10. Kim TH, Kim YE, Ahn S, Kim JY, Ki CS, Oh YL, et al. TERT promoter mutations and long-term survival in patients with thyroid cancer. Endocr Relat Cancer 2016;23:813–823. 27528624.

11. Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH, et al. Effects of coexistent BRAF(V600E) and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 2017;27:651–660. 28181854.

12. Sidaway P. Thyroid cancer: BRAF and/or TERT mutations increase mortality. Nat Rev Clin Oncol 2016;13:652.

13. Liu R, Bishop J, Zhu G, Zhang T, Ladenson PW, Xing M. Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol 2017;3:202–208.

14. Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual 7th edth ed. New York: Springer; 2010.

15. Hassan A, Razi M, Riaz S, Khalid M, Nawaz MK, Syed AA, et al. Survival analysis of papillary thyroid carcinoma in relation to stage and recurrence risk: a 20-year experience in Pakistan. Clin Nucl Med 2016;41:606–613. 27124680.

16. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. Eur J Cancer 2017;77:140–152. 28410490.

17. Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid 2016;26:373–380. 26914539.

18. Kim M, Kim YN, Kim WG, Park S, Kwon H, Jeon MJ, et al. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years? Clin Endocrinol (Oxf) 2017;86:438–443. 27731521.

19. Amin MB, Edge SB, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual 8th edth ed. Chicago: Springer International Publishing; 2017.

20. Kim M, Kim WG, Oh HS, Park S, Kwon H, Song DE, et al. Comparison of the seventh and eighth editions of the American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis staging system for differentiated thyroid cancer. Thyroid 2017;27:1149–1155. 28635571.

21. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Prognostic significance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg 2006;30:780–786. 16411013.

22. Woo CG, Sung CO, Choi YM, Kim WG, Kim TY, Shong YK, et al. Clinicopathological significance of minimal extrathyroid extension in solitary papillary thyroid carcinomas. Ann Surg Oncol 2015;22(Suppl 3):S728–S733. 26077913.

SUPPLEMENTARY MATERIAL

Supplemental Table S1

Baseline Characteristics of Differentiated Thyroid Cancer Patients with Disease-Specific Mortality According to the Duration from Initial Diagnosis to Mortality

enm-32-434-s001.pdf

Article information Continued

Korean Endocrine Society

(open-access, http://creativecommons.org/licenses/by-nc/4.0/) :

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Funded by : Korean Endocrine Society

Table 1

Baseline Characteristics of Differentiated Thyroid Cancer Patients

Characteristic		No. (%)	Mean±SD
Age, yr			46.2±12.3
	≥45	4,308 (53)	46.2±12.3
Female sex		6,971 (87)
Extent of initial operation
	Lobectomy	1,227 (15)
	Total thyroidectomy	6,831 (85)
RAI ablation therapy (yes)		5,837 (72)
Pathology
	PTC	7,780 (97)
	FTC	278 (3)
Size of primary tumor, cm			1.6±1.0
	≤2	6,059 (75)
	2.1–4.0	1,652 (21)
	>4	347 (4)
Extra-thyroidal extension
	Microscopic	3,707 (46)
	Gross	253 (3)
T stage
	T1	3,277 (41)
	T2	600 (7)
	T3	3,870 (48)
	T4	311 (4)
N stage
	N0/Nx	4,840 (60)
	N1a	2,353 (29)
	N1b	865 (11)
M stage
	M1	108 (1.3)
TNM stage
	Stage I	4,999 (62)
	Stage II	196 (2)
	Stage III	2,288 (28)
	Stage IV	575 (7)

TNM stage was determined using the 7th edition of the American Joint Committee on Cancer TNM staging system.

SD, standard deviation; RAI, radioactive iodine; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; TNM, tumor node metastasis.

Table 2

Pathological Characteristics of Differentiated Thyroid Cancer Patients According to the Year of Initial Diagnosis

Characteristic		Year of initial diagnosis		P value
Characteristic		1996–2000 (n=1,672, 21%)	2001–2005 (n=6,386, 79%)	P value
Pathology				<0.001
	PTC	1,441 (86)	5,904 (92)
	FTC	231 (14)	482 (8)
Size of primary tumor, cm				<0.001
	≤2	984 (59)	5,075 (79)
	2.1–4.0	563 (34)	1,089 (17)
	>4	125 (7)	222 (3)
Extra-thyroidal extension				0.56
	Microscopic	769 (46)	2,938 (46)
	Gross	59 (4)	194 (3)
LN metastasis				<0.001
	N0/Nx	884 (53)	3,956 (62)
	N1a	567 (34)	1,786 (28)
	N1b	221 (13)	644 (10)
TNM stage				<0.001
	Stage I	1,037 (62)	3,962 (62)
	Stage II	71 (4)	125 (2)
	Stage III	418 (25)	1,870 (29)
	Stage IV	146 (9)	429 (7)

P value was evaluated by the chi-square test. TNM stage was determined by the 7th American Joint Committee on Cancer TNM staging system.

PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; LN, lymph node; TNM, tumor node metastasis.

Table 3

Risk Factors of Disease-Specific Mortality of Differentiated Thyroid Cancer Patients

Variable		Univariate analysis			Multivariate analysis #1^a			Multivariate analysis #2^b
Variable		HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Age, yr
	≥45	9.04	5.21–15.68	<0.001	9.68	5.54–16.91	<0.001	3.44	1.44–8.20	0.005
Female sex		0.40	0.28–0.57	<0.001	0.67	0.45–0.97	0.037	0.61	0.42–0.89	0.009
Pathology
	PTC	Ref			Ref			Ref
	FTC	3.20	2.20–4.65	<0.001	2.44	1.56–3.81	<0.001	2.88	1.86–4.46	<0.001
Size of primary tumor, cm
	≤2	Ref			Ref			Ref
	2.1–4.0	3.10	2.13–4.52	<0.001	2.15	1.44–2.78	<0.001	1.82	1.21–2.74	0.004
	>4	12.46	8.33–18.62	<0.001	5.17	3.23–8.29	<0.001	4.63	2.92–7.33	<0.001
Extra-thyroidal extension
	No	Ref						Ref
	Microscopic	2.47	1.67–3.65	<0.001	2.19	1.43–3.35	<0.001	1.90	1.14–3.15	0.014
	Gross	13.73	8.46–22.31	<0.001	4.70	2.68–8.25	<0.001	2.63	1.42–4.89	0.002
LN metastasis
	N0/Nx	Ref			Ref
	N1a	0.79	0.51–1.22	0.28	0.77	0.49–1.22	0.270
	N1b	3.48	2.42–5.02	<0.001	1.81	1.18–2.78	0.007
Distant metastasis
	No	Ref			Ref
	Yes	18.04	12.00–27.10	<0.001	7.55	4.81–11.83	<0.001
TNM stage
	Stage I	Ref
	Stage II	10.60	4.82–23.32	<0.001				2.78	1.07–7.20	0.036
	Stage III	5.27	3.12–8.90	<0.001				1.58	0.67–3.70	0.290
	Stage IV	35.25	21.52–57.73	<0.001				7.21	3.05–17.06	<0.001

TNM stage was determined by the 7th American Joint Committee on Cancer TNM staging system.

HR, hazard ratio; CI, confidence interval; PTC, papillary thyroid cancer; FTC, follicular thyroid cancer; LN, lymph node; TNM, tumor node metastasis.

^aIn multivariate analysis #1, we used age at diagnosis, sex, pathology, primary tumor size, presence of extrathyroidal extension, cervical LN metastasis, and distant metastasis as possible risk factors; ^bIn multivariate analysis #2, we used age at diagnosis, sex, pathology, primary tumor size, presence of extrathyroidal extension, and TNM staging as possible risk factors.